{"ticker": {"uuid": "11fae724-da6d-4f62-832b-e428559d0baa", "symbol": "HYL", "name": "Hyloris Pharmaceuticals SA", "exchange": "BRU", "country": "BE", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Hyloris Secures New China Licensing Pathway for Maxigesic IV", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNb3VfOVlkbUxZOU9ZajBjNHR4OEx6ZjVSdE1nSE10WmdhcnltZUdrZXpaMkhlLUFZRE1DRkRzVEQzcXVIMV9GbnVHOWZpamZJb1Y0bzFSTzZQQXhSVHRqTUpJVDFoX2huR2tnNUFYcHBPaEFUMzRqT21RN1UtQ2M0ckVlUWJnR1NiVGNFVFFMZzlUNGlGNmhRekNuN25SaDRhdzlHYVlFQlIwRmRScGxRMzRn?oc=5", "source_name": "TipRanks", "published_at": "2026-07-15T01:35:23+00:00", "published_display": "15 Jul 2026 01:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "When Will Hyloris Pharmaceuticals SA (EBR:HYL) Become Profitable?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTFB2YzMwd3pLd3pNR1pRQlAzY1VReVF1aXREZmpyTktta2l4bTQtY1dlUUFzamhIeGt5NzJMRlpvT2N1ejRoWVVPeFBaYVlXM2tscEprcFRvOGVQTngzN256T19nd1lkQQ?oc=5", "source_name": "webull.com.my", "published_at": "2025-12-31T08:00:00+00:00", "published_display": "31 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hyloris announces U.S. FDA Approval of Maxigesic\u00ae IV", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQQnBJUWZTUnVLRUdIdUxOSFlVMmsybnU1b2VPVEd5blNPVTFNZE1uV2JqOUJiOGx0Mm8wMWdCajhsRkFWZFI0dGxVcF9ON01STXBncUplczhMZ2pSMVFSX2ExNWFTRG1ZdEhDSzh0ME9CYkVVZUc0b3h5Q3B1YnhZY1p0U0pXdHhoQXl3eXEyOHlwdEtDS0wzajVReU55R2FOLXhNWmdPOHdVRFlYYWxZb2V0Rmdkdkw3TWNaNGpfNA?oc=5", "source_name": "GlobeNewswire", "published_at": "2023-10-18T07:00:00+00:00", "published_display": "18 Oct 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hyloris releases Annual Report 2022, including ESG objectives", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxQSk1pdHhtRFNLYzRTSnhJUFdvV2lMLU5HT0Jqa2ZmeGJCNUc1S2VmZUF5dDBVWks2UnhaWmVIMW0xOEhGZW1aOUZqS1ZZSFRkdVcwMC1OaWV3SkFkNURubjRBZHFjMzZMeFdSWm9QeThhdExfMGdLLW9iOEtySUtBckhDY1h4UkZU?oc=5", "source_name": "Market source", "published_at": "2023-04-27T07:00:00+00:00", "published_display": "27 Apr 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hyloris announces submission of Maxigesic\u00ae IV packaging data requested by the US FDA", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPa1labGpTOXV5Q2VQZDBrNjlEMUFuTFNyZl9faXJFTHBXQ0Z0d2xXZHo5R25NLWNKMG9LS3Z1dmh1blZTMndaV2J6YTR3Z2VnNHV3RWEtbUJCNjNoSWVJRmJQWGl4Wk00T1JUN0FocVluUmhEMzhSQW1zM2lPekVEaUgwc3ozQS1TV1FOVjhOMkNONXkw?oc=5", "source_name": "Market source", "published_at": "2023-04-17T07:00:00+00:00", "published_display": "17 Apr 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hyloris Pharmaceuticals Announces Move to L\u00e9giaPark Complex", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gJBVV95cUxNai0wWFlCWU9lZGFXRnA2OW5GR3U5SjJac29iRW05X2JkTkFTTkw2aWZ5MnMyT25BMVNSNEdvWHN0TEV0VFJTMUhEdnU0MHBZNmZDMmZmMXg3bGNNWUhhQUxEeVptRXhYbDdFVDR0cWFaYmxSOVY4dDkxNXV0NDNQVjBHeTRBaGxYNXJWUTJSSF83MVFVRzdOdzhLbXdaamdNRWlsMWNfQ1N1dlBfeXlsN1hROEdHRXpGYnp4VGRyRkE1UTdIWlBpQzFWc1hyeW5WZ2EwenNOWWtCWnZ0UDFqQUVnem9OS2ZzVnI1OVp2RWdIRmhXMVFQOW1tYTZqUmJsVTZKZWN0T3FJaURJSzc1Mk85eE1mRE8xSGFURkFKZmwwMzdyVEdvZGdyRUxmUE5UNGlPUVc3bVNaWUEzWjBWTTJRc0R6dk9PLXpPak5YWDZ4dw?oc=5", "source_name": "GlobeNewswire", "published_at": "2022-10-12T07:00:00+00:00", "published_display": "12 Oct 2022 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hyloris Successfully Renegotiates License Agreements for Lead Products with the Alter Pharma Group", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_wFBVV95cUxOSnRlN2pMOFJiVkJSREk4dHI5SjBfNWFZNDlybVZXNXlwUmx3WWpwS1pTamZLSzBHenRBdDIzdURUUnBXMHFxVzI4U0o4am1ja3d6OXEzUlNPVHhKc2Rjd0VkVkFySGltTGVubnM1TUJjeDJ5NExSa21SQV9YUDVrV3BCaFlKYTB5aEpDYm9DdmRRUnpRNlBYeUpzOFhQQmxESDFZeXJ2aEhyUGVzc1JHbEdfRnhfTFRtM1RBVHlmclVFTWtOVGVkblkzRkQzSlBxcUZxUzdCeWhnMHpkQm9qdk51VjJyZzBNeGllbkNKV2pLaldweWJ3WlJ3aS1FQVE?oc=5", "source_name": "GlobeNewswire", "published_at": "2021-06-24T07:00:00+00:00", "published_display": "24 Jun 2021 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hyloris Announces Major Commercial Partnership in the U.S. for Maxigesic\u00ae IV", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxOWVNHcloxeWdqWk5MY1pZRXd5Z0ZRT1R0dDdvcWhTT0JNS1VudXl5dlVMNlpONHFNa0RZd2VRc1phY3dLZG12cE5MMlpQaUJsN0V6Nk8zdndIbGczc3dRQWhQSlhVbGxYNGdUZms4aVhMc05QWjVxSzZLYU1aaTJ0bWZacV91STZmcERwalRPdF9iU19TWFJvWXY1ay0yNVhqY0p2aFpuQTlfMHVEaDhGem5uT2xUTlJaZ2lSRVNidGdlb2xMcTRfYkRfX0U3N1NOaURTLXRZTUhTYnAtNnN3?oc=5", "source_name": "GlobeNewswire", "published_at": "2021-04-28T07:00:00+00:00", "published_display": "28 Apr 2021 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Hyloris Secures New China Licensing Pathway for Maxigesic IV", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNb3VfOVlkbUxZOU9ZajBjNHR4OEx6ZjVSdE1nSE10WmdhcnltZUdrZXpaMkhlLUFZRE1DRkRzVEQzcXVIMV9GbnVHOWZpamZJb1Y0bzFSTzZQQXhSVHRqTUpJVDFoX2huR2tnNUFYcHBPaEFUMzRqT21RN1UtQ2M0ckVlUWJnR1NiVGNFVFFMZzlUNGlGNmhRekNuN25SaDRhdzlHYVlFQlIwRmRScGxRMzRn?oc=5", "source_name": "TipRanks", "published_at": "2026-07-15T01:35:23+00:00", "published_display": "15 Jul 2026 01:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "When Will Hyloris Pharmaceuticals SA (EBR:HYL) Become Profitable?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTFB2YzMwd3pLd3pNR1pRQlAzY1VReVF1aXREZmpyTktta2l4bTQtY1dlUUFzamhIeGt5NzJMRlpvT2N1ejRoWVVPeFBaYVlXM2tscEprcFRvOGVQTngzN256T19nd1lkQQ?oc=5", "source_name": "webull.com.my", "published_at": "2025-12-31T08:00:00+00:00", "published_display": "31 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hyloris announces U.S. FDA Approval of Maxigesic\u00ae IV", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQQnBJUWZTUnVLRUdIdUxOSFlVMmsybnU1b2VPVEd5blNPVTFNZE1uV2JqOUJiOGx0Mm8wMWdCajhsRkFWZFI0dGxVcF9ON01STXBncUplczhMZ2pSMVFSX2ExNWFTRG1ZdEhDSzh0ME9CYkVVZUc0b3h5Q3B1YnhZY1p0U0pXdHhoQXl3eXEyOHlwdEtDS0wzajVReU55R2FOLXhNWmdPOHdVRFlYYWxZb2V0Rmdkdkw3TWNaNGpfNA?oc=5", "source_name": "GlobeNewswire", "published_at": "2023-10-18T07:00:00+00:00", "published_display": "18 Oct 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hyloris releases Annual Report 2022, including ESG objectives", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxQSk1pdHhtRFNLYzRTSnhJUFdvV2lMLU5HT0Jqa2ZmeGJCNUc1S2VmZUF5dDBVWks2UnhaWmVIMW0xOEhGZW1aOUZqS1ZZSFRkdVcwMC1OaWV3SkFkNURubjRBZHFjMzZMeFdSWm9QeThhdExfMGdLLW9iOEtySUtBckhDY1h4UkZU?oc=5", "source_name": "Market source", "published_at": "2023-04-27T07:00:00+00:00", "published_display": "27 Apr 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hyloris announces submission of Maxigesic\u00ae IV packaging data requested by the US FDA", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPa1labGpTOXV5Q2VQZDBrNjlEMUFuTFNyZl9faXJFTHBXQ0Z0d2xXZHo5R25NLWNKMG9LS3Z1dmh1blZTMndaV2J6YTR3Z2VnNHV3RWEtbUJCNjNoSWVJRmJQWGl4Wk00T1JUN0FocVluUmhEMzhSQW1zM2lPekVEaUgwc3ozQS1TV1FOVjhOMkNONXkw?oc=5", "source_name": "Market source", "published_at": "2023-04-17T07:00:00+00:00", "published_display": "17 Apr 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hyloris Pharmaceuticals Announces Move to L\u00e9giaPark Complex", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gJBVV95cUxNai0wWFlCWU9lZGFXRnA2OW5GR3U5SjJac29iRW05X2JkTkFTTkw2aWZ5MnMyT25BMVNSNEdvWHN0TEV0VFJTMUhEdnU0MHBZNmZDMmZmMXg3bGNNWUhhQUxEeVptRXhYbDdFVDR0cWFaYmxSOVY4dDkxNXV0NDNQVjBHeTRBaGxYNXJWUTJSSF83MVFVRzdOdzhLbXdaamdNRWlsMWNfQ1N1dlBfeXlsN1hROEdHRXpGYnp4VGRyRkE1UTdIWlBpQzFWc1hyeW5WZ2EwenNOWWtCWnZ0UDFqQUVnem9OS2ZzVnI1OVp2RWdIRmhXMVFQOW1tYTZqUmJsVTZKZWN0T3FJaURJSzc1Mk85eE1mRE8xSGFURkFKZmwwMzdyVEdvZGdyRUxmUE5UNGlPUVc3bVNaWUEzWjBWTTJRc0R6dk9PLXpPak5YWDZ4dw?oc=5", "source_name": "GlobeNewswire", "published_at": "2022-10-12T07:00:00+00:00", "published_display": "12 Oct 2022 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hyloris Successfully Renegotiates License Agreements for Lead Products with the Alter Pharma Group", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_wFBVV95cUxOSnRlN2pMOFJiVkJSREk4dHI5SjBfNWFZNDlybVZXNXlwUmx3WWpwS1pTamZLSzBHenRBdDIzdURUUnBXMHFxVzI4U0o4am1ja3d6OXEzUlNPVHhKc2Rjd0VkVkFySGltTGVubnM1TUJjeDJ5NExSa21SQV9YUDVrV3BCaFlKYTB5aEpDYm9DdmRRUnpRNlBYeUpzOFhQQmxESDFZeXJ2aEhyUGVzc1JHbEdfRnhfTFRtM1RBVHlmclVFTWtOVGVkblkzRkQzSlBxcUZxUzdCeWhnMHpkQm9qdk51VjJyZzBNeGllbkNKV2pLaldweWJ3WlJ3aS1FQVE?oc=5", "source_name": "GlobeNewswire", "published_at": "2021-06-24T07:00:00+00:00", "published_display": "24 Jun 2021 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hyloris Announces Major Commercial Partnership in the U.S. for Maxigesic\u00ae IV", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxOWVNHcloxeWdqWk5MY1pZRXd5Z0ZRT1R0dDdvcWhTT0JNS1VudXl5dlVMNlpONHFNa0RZd2VRc1phY3dLZG12cE5MMlpQaUJsN0V6Nk8zdndIbGczc3dRQWhQSlhVbGxYNGdUZms4aVhMc05QWjVxSzZLYU1aaTJ0bWZacV91STZmcERwalRPdF9iU19TWFJvWXY1ay0yNVhqY0p2aFpuQTlfMHVEaDhGem5uT2xUTlJaZ2lSRVNidGdlb2xMcTRfYkRfX0U3N1NOaURTLXRZTUhTYnAtNnN3?oc=5", "source_name": "GlobeNewswire", "published_at": "2021-04-28T07:00:00+00:00", "published_display": "28 Apr 2021 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 59, "total_relevant": 8, "sentiment_summary": {"positive": 0, "negative": 0, "neutral": 8, "score": 50, "total": 8, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 3.3, "count": 6}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 0, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 4.62, "latest_week": "2026-07-17", "one_week_move": -0.6, "four_week_move": 0.2, "twelve_week_move": -15.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.231879, "market_dynamics_buy_signal": false, "relative_strength": -29.387879, "fair_value_gap": -42.0, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 42.5214, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.6% over one week, +0.2% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 48, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "GlobeNewswire", "count": 4}, {"label": "Market source", "count": 2}, {"label": "TipRanks", "count": 1}, {"label": "webull.com.my", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 8}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 6}, {"label": "Regulatory and legal", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "8", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-0.6% over one week, +0.2% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Hyloris Secures New China Licensing Pathway for Maxigesic IV"}], "updated_at": "2026-07-18T08:48:32.083097+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}